BiotechTube

Sensipar (Cinacalcet HCl)

Phase 2Completed
0 watching 0 views this week⚡ Active
51
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Secondary Hyperparathyroidism

Conditions

Secondary Hyperparathyroidism

Trial Timeline

May 1, 2006 → May 1, 2011

NCT ID
NCT00261950

About Sensipar (Cinacalcet HCl)

Sensipar (Cinacalcet HCl) is a phase 2 stage product being developed by Amgen for Secondary Hyperparathyroidism. The current trial status is completed. This product is registered under clinical trial identifier NCT00261950. Target conditions include Secondary Hyperparathyroidism.

Hype Score Breakdown

Clinical
17
Activity
12
Company
9
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT00261950Phase 2Completed

Competing Products

20 competing products in Secondary Hyperparathyroidism

See all competitors
ProductCompanyStageHype Score
ASP7991 + Cinacalcet + PlaceboAstellas PharmaPhase 2
52
FycompaEisaiPre-clinical
23
FycompaEisaiPre-clinical
23
KHK7580 + KRN1493Kyowa KirinPhase 2/3
65
KHK7580Kyowa KirinPhase 1
33
KHK7580Kyowa KirinPhase 3
77
KHK7580Kyowa KirinPhase 3
77
Cinacalcet HClKyowa KirinApproved
85
KHK7580 + Cinacalcet HydrochlorideKyowa KirinPhase 3
77
Placebo + KHK7580 low dose + KHK7580 middle dose + KHK7580 high dose + KRN1493Kyowa KirinPhase 2
52
dirucotide + PlaceboEli LillyPhase 2/3
65
dirucotideEli LillyPhase 2/3
65
Paricalcitol + CalcitriolAbbViePre-clinical
23
paricalcitol + maxacalcitol + paricalcitol placebo + maxacalcitol placeboAbbViePhase 3
77
Paricalcitol + CalcifediolAbbVieApproved
85
Paricalcitol + Darbepoetin alfaAbbVieApproved
85
Birabresib Dose 20 mgMerckPhase 1
33
Remibrutinib (blinded) + Placebo + Remibrutinib (Open label)NovartisPhase 3
77
RanibizumabNovartisApproved
85
BAF312 + Baseline disease modifying therapies (DMTs) + BNT162 + mRNA-1273NovartisApproved
85

Other Products from Amgen

Aranesp®Approved
84
PanitumumabApproved
84
EvolocumabApproved
84
Prolia®Approved
84
EvolocumabApproved
84